InvestorsHub Logo
Followers 8
Posts 357
Boards Moderated 0
Alias Born 07/30/2015

Re: None

Thursday, 11/12/2015 11:54:53 PM

Thursday, November 12, 2015 11:54:53 PM

Post# of 6314
Nice Seeking Alpha article out today discussing the Midtown Partners recent research report with a price target of $2.50 per share. It also discusses the strength of their lead glaucoma candidate. Again, I would take what Nemus has in their pipeline over what GWPH and Zynerba have combined. They're sitting on 40 years of cannabis research and development. The quality of the people involved is a good indication of what Nemus has.